Business
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
Insider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (“NTHI” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapie
About this update from Neonc Technologies Holdings, Inc.
[{"type":"image","alt":"NeOnc Technologies Holdings, Inc.","displaySize":"","headline":null,"caption":"NeOnc Technologies Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o4p8_hWKHEoe_S6DjNy.mA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMA--/https://media.zenfs.com/en/globenewswire.com/b347a68adadea2a3bd45b7a77e70bf38","width":300,"height":93}},"lazy":false},{"type":"text","content":"Insider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts:","length":113,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"NEO100: interim data readout - expected within ~4 months ","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"NEO212: expects Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study - within the next 4 weeks ","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":191,"olType":false},{"type":"text","content":"CALABASAS, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (“NTHI” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that Chairman and CEO Amir Heshmatpour has purchased approximately $300,000 worth of NTHI stock in the last week, demonstrating management's confidence in the Company's undervalued shares, ahead of multiple near-term catalysts which include:","length":506,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"NEO100 - interim data readout - expected within ~4 months","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"NEO212 - Type B End-of-Phase FDA meeting to align on a potential pivotal, registrational Phase 2 study – expected within the next 4 weeks","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":194,"olType":false},{"type":"text","content":"The company is also providing additional context regarding the year-over-year change in operating expenses reflected in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on March 31, 2026.","length":220,"tagName":"p"},{"type":"text"...